Amedisys entered into a new $225 million unsecured credit facility agreement and an amendment to its senior notes. to ensure financing.
The new credit facility is with a group of banks led by JPMorgan Chase Bank, N.A. and Bank of America Merrill Lynch, as joint book runners for this financing transaction.
The new facility includes a $165 million five-year revolving credit facility and a $60 million five-year amortizing term loan.
For further deal information visit Current Agreements (subscription required)
Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Financing Scorecard – view top life science financing deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity